B
Brodie Daniels
Researcher at South African Medical Research Council
Publications - 20
Citations - 531
Brodie Daniels is an academic researcher from South African Medical Research Council. The author has contributed to research in topics: Medicine & Breastfeeding. The author has an hindex of 10, co-authored 16 publications receiving 409 citations. Previous affiliations of Brodie Daniels include University of KwaZulu-Natal & Nelson Mandela Metropolitan University.
Papers
More filters
Journal ArticleDOI
Women and HIV in Sub-Saharan Africa
TL;DR: There is no magic bullet and behavior alone is unlikely to change the course of the epidemic, but substantial progress has been made in biomedical, behavioral and structural strategies for HIV prevention with attendant challenges of developing appropriate HIV prevention packages which take into consideration the socioeconomic and cultural context of women in society at large.
Journal ArticleDOI
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial
Linda-Gail Bekker,Zoe Moodie,Nicole Grunenberg,Fatima Laher,Georgia D. Tomaras,Kristen W. Cohen,Mary Allen,Mookho Malahleha,Kathryn Therese. Mngadi,Brodie Daniels,Craig Innes,Carter Bentley,Nicole Frahm,Daryl E. Morris,Lynn Morris,Nonhlanhla N. Mkhize,David C. Montefiori,Marcella Sarzotti-Kelsoe,Shannon Grant,Chenchen Yu,Vijay L. Mehra,Michael Pensiero,Sanjay Phogat,Carlos A. DiazGranados,Susan W. Barnett,Niranjan Kanesa-thasan,Marguerite Koutsoukos,Nelson L. Michael,Merlin L. Robb,James G. Kublin,Peter B. Gilbert,Lawrence Corey,Glenda Gray,Glenda Gray,Glenda Gray,M. Juliana McElrath +35 more
TL;DR: The IgG response to the HVTN 100 vaccine was lower than that reported in RV144, but it exceeded the predicted 63% threshold needed for 50% vaccine efficacy using a V1V2 correlate of protection model, and qualified for phase 2b/3 efficacy testing.
Journal ArticleDOI
Cotrimoxazole Prophylaxis Increases Resistance Gene Prevalence and α-Diversity but Decreases β-Diversity in the Gut Microbiome of Human Immunodeficiency Virus-Exposed, Uninfected Infants.
Alaric W. D’Souza,Eshia Moodley-Govender,Bertram M. Berla,Tejas Kelkar,Bin Wang,Xiaoqing Sun,Brodie Daniels,Brodie Daniels,Anna Coutsoudis,Indi Trehan,Indi Trehan,Gautam Dantas +11 more
TL;DR: In this paper, the authors analyzed whole-metagenome sequencing data from 163 longitudinally collected stool samples from 63 HEU infants randomized to receive or not receive prophylactic cotrimoxazole treatment.
Journal ArticleDOI
Safety and immune responses after a 12-month booster in healthy HIV-uninfected adults in HVTN 100 in South Africa: A randomized double-blind placebo-controlled trial of ALVAC-HIV (vCP2438) and bivalent subtype C gp120/MF59 vaccines
Fatima Laher,Zoe Moodie,Kristen W. Cohen,Nicole Grunenberg,Linda-Gail Bekker,Mary Allen,Nicole Frahm,Nicole L. Yates,Lynn Morris,Lynn Morris,Mookho Malahleha,Kathryn Therese. Mngadi,Brodie Daniels,Craig Innes,Kevin O. Saunders,Shannon Grant,Chenchen Yu,Peter B. Gilbert,Sanjay Phogat,Carlos A. DiazGranados,Marguerite Koutsoukos,Olivier Van Der Meeren,Carter Bentley,Nonhlanhla N. Mkhize,Nonhlanhla N. Mkhize,Michael Pensiero,Vijay L. Mehra,James G. Kublin,Lawrence Corey,David C. Montefiori,Glenda Gray,Glenda Gray,M. Juliana McElrath,Georgia D. Tomaras +33 more
TL;DR: Less waning of immune responses was seen after the fifth vaccination than after the fourth, with higher antibody and cellular response rates at month 18 than at month 12.
Journal ArticleDOI
Effect of co-trimoxazole prophylaxis on morbidity and mortality of HIV-exposed, HIV-uninfected infants in South Africa: a randomised controlled, non-inferiority trial
Brodie Daniels,Anna Coutsoudis,Eshia Moodley-Govender,Helen Mulol,Elizabeth Spooner,Elizabeth Spooner,Photini Kiepiela,Shabashini Reddy,Linda Zako,Nhan T. Ho,Louise Kuhn,Gita Ramjee +11 more
TL;DR: This randomised controlled, non-inferiority trial aimed to investigate whether receiving no co-trimoxazole prophylaxis for HIV-exposed, HIV-uninfected infants is inferior to receiving co- TrIMoxazoles for HIV prevention in the resulting incidence of grade 3 or 4 common childhood illnesses or mortality in breastfed HIV-Exposed,AIDS-un Infected infants.